Opdualag(Nivolumab and Relatlimab) Side Effects

This section describes the common and serious adverse reactions associated with OPDUALAG.

Adverse Reactions

OPDUALAG can cause severe and fatal immune-mediated adverse reactions (IMARs) affecting various organs, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatitis, and myocarditis. The most common adverse reactions (≥20%) observed in patients are musculoskeletal pain, fatigue, rash, pruritus, and diarrhea. Frequent laboratory abnormalities include decreased hemoglobin, lymphocytopenia, and elevated liver enzymes. Infusion-related reactions can also occur. Management often involves corticosteroids, hormone replacement, and protocol-defined dosage interruptions or discontinuation based on the severity of the reaction.